CRYL1 is a Potential Prognostic Biomarker of Clear Cell Renal Cell Carcinoma Correlated with Immune Infiltration and...

Area of Science:

• Oncology
• Genomics
• Biomarker Discovery

Background:

• Clear cell renal cell carcinoma (ccRCC) is a prevalent cancer with unsatisfactory treatment outcomes.
• Identifying novel biomarkers is crucial for early diagnosis, therapy, and prognosis prediction in ccRCC.

Purpose of the Study:

• To identify and validate independent prognostic biomarkers for clear cell renal cell carcinoma (ccRCC).
• To investigate the molecular mechanisms and functional roles of identified biomarkers in ccRCC progression.

Main Methods:

• Utilized GEO datasets, differential gene expression (DEG) analysis, and weighted gene coexpression network analysis (WGCNA).
• Applied LASSO, random forest, and Cox regression for biomarker identification.
• Validated biomarker function through in vitro assays (wound healing, transwell, colony formation, flow cytometry) and immunohistochemistry (IHC).

Main Results:

• CRYL1 was identified as an independent prognostic biomarker for ccRCC (HR=2.01, P<0.001).
• Higher CRYL1 expression correlated with improved disease-free survival (DFS) and overall survival (OS).
• CRYL1 impacts sugar/fat/amino acid metabolism, cuproptosis-related pathways, and immune cell infiltration, and its silencing promotes ccRCC cell migration and proliferation.

Conclusions:

• CRYL1 serves as a robust predictive marker for clinicopathological characteristics and survival in ccRCC patients.
• CRYL1 holds potential as a therapeutic target for ccRCC.